The conference will cover important progress made in the areas of therapeutic protein immunogenicity and immunotoxicity evaluation such as protein aggregation, clinical relevance and assessment of immunogenicity, mitigation of immunogenicity-related risks, biosimilar development, and immunotoxicity evaluation strategies.

The Immunogenicity and Immunotoxicity Conference will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.

Sessions for the 2015 program:
I. Immunotoxicity Evaluation of Novel Drug Candidates
II. Immunotoxicity and Drug Hypersensitivity
III. Immunogenicity Assessment for Biosimilars
IV. Immunogenicity Assessment for Peptide Therapeutics
V. Protein Aggregation, Biological Activity and Immunogenicity
VI. Computational Methods for Immunogenicity Evaluation
VII. Innate Response & Adverse Immunogenicity (Joint session with Innate Immunity Conference)